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Background/Aims: This study sought to determine the 
natural course of Crohn’s disease (CD) and identify predic-
tors that could indicate responsiveness to corticosteroid (CS) 
therapy. Methods: Patients with active CD who were treated 
with oral CS at a single institution between August 1994 and 
February 2008 were retrospectively reviewed. The clinical 
outcomes at 1 month, 4 months, and 1 year after the treat-
ment, as well as clinical and biochemical parameters at the 
time of CS initiation, were evaluated. Results: A total of 96 
patients with CD were enrolled. In this study, 37 patients 
achieved complete remission (38.5%), 49 achieved partial 
remission (51.0%), and 10 (10.4%) showed no response at 
1 month after the initiation of CS treatment. At 4 months 
and 1 year after treatment, 66 (69.5%) and 47 (56.6%) 
patients showed prolonged response, 22 (23.2%) and 20 
(24.1%) showed steroid dependency, and 7 (7.4%) and 16 
(19.3%) showed refractoriness, respectively. Nonstricturing 
and nonpenetrating behaviors and a lower CD activity index 
demonstrated clinical significance for mid-term or mid- and 
long-term steroid responses, respectively. Conclusions: The 
short-term response rate to initial oral CS therapy in CD was 
considerably high, but responsiveness thereafter showed a 
tendency to decrease with time. Clinical parameters reflect-
ing mild inflammation were associated with responsiveness 
after CS treatment. (Gut Liver 2013;7:58-65)
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INTRODUCTION
Crohn’s disease (CD) is a lifelong illness characterized by re-
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current chronic inflammation of the gastrointestinal tract with-
out a known exact etiology. Lesions of CD commonly involve 
the terminal ileum and proximal colon, but the entire gastroin-
testinal tract can be affected.1 The goals of treatment for CD are 
to induce complete remission (CR) of the disease, maintain the 
remission, and minimize the risk of complications and surgery.
The use of corticosteroids (CS) has been a well-established 
treatment for active inflammatory bowel disease (IBD) since 
Truelove and Witts2 reported that oral cortisone could effective-
ly induce remission of ulcerative colitis (UC) in 1955. After the 
National Cooperative Crohn’s Disease Study and the European 
Cooperative Crohn’s Disease Study showed that CS could also 
effectively induce remission in patients with CD, CS have been 
widely used to treat the disease for the past 50 years.3,4
While many investigators have reported the usefulness of CS 
in treating CD,5-8 systemically available CS are associated with 
various side effects.9 It is still difficult to decide when to start or 
discontinue CS because of drug dependence that may develop 
during long-term use of CS and repeated surgery risk when 
there is unresponsiveness to the treatment with CS.10 Further-
more, CS are known to be ineffective in maintaining remission 
of CD.11
So far, there have been few papers that have described the 
natural course of CD in patients after administration of first 
course CS. Furthermore, most of the published researches were 
conducted in Western countries. However, the natural course of 
CD appears to differ somewhat in Asians compared to Western 
populations. Asian patients tend to experience a milder clinical 
course, lower relapse rate, and lower surgery rate.12-16 The aim of 
this study was to determine the natural course of CD in patients 
who were first treated with oral CS and to find predictive factors 
that can indicate their responsiveness to such steroid therapy.
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MATERIALS AND METHODS
1. Patients
All active CD patients who were diagnosed and treated with 
oral CS between August 1994 and February 2008 at Severance 
Hospital in Seoul, Korea were enrolled, and their medical records 
were retrospectively reviewed. The data for all 239 patients with 
CD treated with CS were retrieved from our internal database 
system and from scanned electronic medical records. Finally, 96 
patients who had received a first course of oral CS therapy were 
enrolled. Patients were excluded from the study according to the 
following criteria: 1) patients who had started CS therapy from 
other clinics (34 patients); 2) those whose precise starting point 
of CS therapy could not be determined (64 patients); 3) those 
who had started on CS intravenously (23 patients); 4) those who 
had no available medical records of the treatment progress (19 
patients); and 5) those who had stopped CS treatment within the 
first month due to any reason (three patients).
2. Definitions of clinical outcomes
The clinical outcomes of the patients were assessed at 1 
month, 4 months, and 1 year after the initiation of CS therapy. 
Short-term responses (1 month after therapy) were classified 
into three groups: CR, partial remission (PR), and no response 
(NR).10,17-19 While CR was defined as the complete resolution of 
active symptoms (absence of blood, pus or mucus in stool, ab-
dominal pain, fever, and decreased stool frequency [≤2/day]), PR 
was defined as the clinical improvement of symptoms, specifi-
cally, the absence of systemic symptoms such as fever or weight 
loss and decreased frequencies of bowel movements (≤4/day), 
abdominal pain, and blood, pus, or mucus in stool.10,18 NR was 
defined as the absence of clinical improvements. Similarly, mid-
term response (at 4 months) and long-term response (at 1 year) 
were categorized into prolonged response, steroid dependency, 
and steroid refractoriness. Prolonged response at 4 months 
was defined as no evidence of clinical recurrence of CD dur-
ing a scheduled tapering or after discontinuation of CS. Steroid 
dependency at 4 months was indicated when the patient was 
unable to taper the dosage for more than 2 weeks or if it was 
necessary to increase the dosage. If the patient showed no clini-
cal improvement at 4 months after CS therapy, he or she was 
classified into the steroid refractory group. Prolonged response 
at 1 year was defined as maintenance of CR or PR without CS, 
while steroid dependency after 1 year indicated the mainte-
nance of CR or PR using CS continuously or occasionally or the 
inability to discontinue the drug. Finally, steroid refractoriness 
at 1 year was defined either as the absence of clinical improve-
ment despite dose increment or the necessity to resort to other 
treatment modalities such as surgery or infliximab.
To analyze predictive factors of clinical outcomes after CS 
treatment, patients exhibiting CR or PR at 1 month after treat-
ment and prolonged response after 4 months and 1 year were 
categorized into the steroid responder group. Patients exhibiting 
NR at 1 month after CS use, steroid dependency, and steroid re-
fractoriness after 4 months and 1 year were categorized into the 
steroid nonresponder group.10,20
3. Clinical and biochemical parameters
The clinical parameters of the patients were assessed by ret-
rospectively reviewing their medical records. The collected data 
included age, sex, duration of the disease, location of CD le-
sions, and behavior of the illness according to the Vienna clas-
sification.21 Medication histories such as initial and total dose of 
oral CS, length of CS use, side effects of CS, and concomitant 
medications (i.e., antibiotics, immunomodulators, or 5-amino 
salicylic acids [5-ASA]) were also obtained for the analysis. Bio-
chemical parameters at the time of initial treatment including C-
reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), 
hemoglobin level, and albumin level were assessed. At each 
visit, every patient completed the center’s standardized CD ques-
tionnaire, which was comprised of questions used to gauge the 
CD activity index (CDAI), and we re-calculated each patient’s 
CDAI at the time of initial CS treatment using the questionnaire.
This study was approved by the Severance Hospital Institu-
tional Review Board, and the Strengthening the Reporting of 
Observational Studies in Epidemiology Statement was used as a 
reference point for key items related to study design and report-
ing.
4. Statistics and analysis
Continuous variables were compared using Mann-Whitney U 
test and are presented in this paper as median (range). Categori-
cal variables were compared by Fisher’s exact test. Logistic re-
gression analysis was performed to identify predictive variables 
for clinical outcomes. The p-values less than 0.05 were con-
sidered statistically significant. All the statistical analyses were 
performed using SPSS version 12.0 for Windows (SPSS Inc., 
Chicago, IL, USA).
RESULTS
1. Clinical characteristics of patients
A total of 96 patients were enrolled from 239 patients with 
CS-treated CD. There were 75 males and 21 females whose 
median age at diagnosis was 23 years (range, 12 to 64 years), 
and the median disease duration was 4 months (range, 0 to 156 
months). The most common location of CD was the ileocolon 
(63.5%) according to the Vienna classification, while 18 patients 
(18.8%) had terminal ileum involvement, 10 (10.4%) had colon 
lesions, and seven had upper gastrointestinal tract involvement 
(7.3%). Nonstricturing, nonpenetrating type (55.2%) was the 
most common CD type; the rest of the cases were either pen-
etrating type (31.3%) or stricturing type (13.5%). The median 
steroid dose was 0.58 mg/kg (range, 0.31 to 0.95 mg/kg), and 
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the median length of initial steroid use was 10 weeks (range, 4 
to 40 weeks). In this study, 95 cases (99.0%) were treated with 
5-ASA as a concomitant medication, 21 cases also used antibi-
otics (21.9%), and three cases used immunomodulators (3.1%). 
During the treatment period, five cases showed complications 
from CS, and three of them discontinued the medication due 
to those side effects. The median CDAI before starting CS treat-
ment was 347.5 (range, 161.4 to 559.8) (Table 1).
2. Response rate to CS treatment
There were 37 CR (38.5%) and 49 PR cases (51.0%), but 10 
patients (10.4%) showed NR to oral CS therapy after one month 
of treatment (Fig. 1). After 4 months, 66 (69.5%) showed pro-
longed response, 22 (23.2%) showed steroid dependency, and 
seven (7.4%) showed refractoriness (six underwent surgery, one 
received immune modulator). After 1 year, 47 patients (56.6%) 
showed prolonged response, 20 (24.1%) showed steroid depen-
dency, and 16 showed refractoriness (19.3%) (Fig. 2). Of the 16 
patients who showed refractoriness, three received infliximab 
therapy, five underwent immunomodulator treatment, and eight 
Fig. 1. Outcomes of steroid use after 1 month of treatment. 
CR, complete response; PR, partial response; NR, no response.
Fig. 2. Outcomes of steroid use after 
4 months and 1 year of treatment. 
Table 1. Baseline Patient Characteristics (n=96)
Characteristic Value
Sex, M/F 75/21
Age at diagnosis, yr 23 (12-64) 
Disease duration, mo 4 (0-156)
Location of disease (by Vienna classification)
   Terminal ileum (L1) 18 (18.8)
   Colon (L2) 10 (10.4)
   Ileocolon (L3) 61 (63.5)
   Upper gastrointestinal tract (L4) 7 (7.3)
Behavior of disease (by Vienna classification)
   Nonstricturing, nonpenetrating type (B1) 53 (55.2)
   Stricturing type (B2) 13 (13.5)
   Penetrating type (B3) 30 (31.3)
Initial dose of oral steroid, mg/kg 0.58 (0.31-0.95)
Total dose of administered oral steroid, mg 1,060.0 (342.5-2,887.5)
Length of initial steroid use, wk 10 (4-40)
Complication of steroids 5 (5.2)
Concomitant medications
   Antibiotics 21 (21.9)
   Immunomodulators 3 (3.1)
   5-Amino salicylic acid 95 (99.0)
C-reactive protein, mg/dL 2.72 (0.10-19.90)
Erythrocyte sedimentation rate, mm/hr 40.5 (2-120)
Hemoglobin, mg/dL 12.2 (5.7-16.4)
Albumin, mg/dL 3.7 (2.1-5.5)
Crohn’s disease activity index 347.5 (161.4-559.8)
Data are presented as median (range) or number (%).
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underwent surgery (Fig. 3).
3. Clinical predictive factors
Clinical characteristics of CS responders and nonresponders 
at one month, 4 months, and 1 year after treatment were com-
pared by univariate analysis. There were no significant dif-
ferences in age, sex, or location of disease at the time of CS 
initiation between responders and nonresponders. Moreover, we 
found no statistically significant differences in the initial dose 
of CS, the duration of its use, and the use of concomitant medi-
cations. However, while nonstricturing, nonpenetrating type 
CD (41 cases, 62.1%) was most commonly seen in responders 
at 4 months, penetrating type CD (15 cases, 51.7%) comprised 
the majority of cases in the nonresponders group, and this was 
statistically significant (p=0.013). The median CDAIs at the time 
of CS initiation of the 1-month, 4-month, and 1-year respond-
ers were 337.0 (range, 161.4 to 474.2), 311.8 (range, 161.4 to 
451.9), and 321.1 (range, 161.4 to 456.6), and those of nonre-
sponders were 386.5 (range, 347.6 to 559.8), 387.8 (range, 293.7 
to 559.8), and 380.6 (range, 208.5 to 471.9), respectively. The 
CDAI at the time of initial CS treatment was significantly higher 
in nonresponders at all time points (p=0.008, p<0.001, and 
p=0.009, respectively). Also, the total dose of steroid was higher 
in the nonresponder group at all time points, and this differ-
ence was statistically significant at 1 month after treatment 
(p=0.032/0.070/0.078, 1 month/4 months/1 year after treatment, 
respectively) (Table 2).
CRP at the time of initial CS treatments showed a statisti-
cally meaningful difference between the responders and non-
responders at 1 month and 4 months (p=0.015 and p=0.009, 
respectively). The median CRP level at 1 year in nonresponders 
was numerically higher than that of responders, but the differ-
ence was not statistically significant. The median values of ESR 
at the time of initial CS treatments in responders at 1 month 
and 4 months were 39.5 mm/hr (range, 2 to 120 mm/hr) and 
38.0 mm/hr (range, 2 to 120 mm/hr), respectively, which were 
significantly lower than 61.5 mm/hr (range, 12 to 120) and 50.0 
mm/hr (range, 4 to 120) in nonresponders, respectively (p=0.043 
and p=0.044, respectively). Responders at all time points tended 
to have numerically higher serum albumin levels at the time of 
CS treatment compared to nonresponders, but the differences 
were not statistically significant (Table 3).
Multivariate analysis was performed for factors including 
age at diagnosis, location of lesions, and disease behavior at 
the time of CS treatment, which are known to be correlated 
with steroid dependency in CD.22 CDAI and biochemical mark-
ers such as CRP, ESR, and serum albumin level at the time of 
initial treatment were also used for the analysis. Nonstricturing, 
nonpenetrating behavior (B1), and lower CDAI were shown to 
be predictors for responders at four months after the treatment 
(p=0.025 and p=0.002, respectively), and CDAI was a statisti-
cally significant predictor of treatment response after 1 year of 
CS therapy (p=0.029) (Table 4).
DISCUSSION
CS therapy is a well-established treatment option for active 
CD. However, despite its usefulness, patients who receive CS 
therapy show a wide spectrum of treatment responses, from CR 
to steroid refractoriness.10,11,17,22-25 Furthermore, CS can cause 
various complications such as musculoskeletal, endocrine, meta-
bolic, gastrointestinal, and skin complications, depending on the 
dosage and duration of usage.22 One study reported that 55% 
of CD patients taking prednisolone (starting dose at 40 mg/day) 
and 33% of CD patients who used budesonide (starting dose at 
9 mg/day) experienced one or more side effects strongly associ-
ated with CS therapy.9 Furthermore, because 70% to 90% of CD 
patients eventually undergo surgery, and 33% to 82% of those 
patients are subjected to repeated surgery,26 possible increases in 
surgery-related mortality due to long term use of CS should be 
taken into consideration. Because of such uncertainty related to 
the use of CS, many clinicians have agonized over the optimal 
Fig. 3. Flow chart of the clinical 
outcomes of patients with active 
Crohn’s disease treated with a first 
course of oral corticosteroids.
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time of initiation and duration of CS treatment.
Several studies have sought to outline the optimal course of 
CS therapy in CD patients and to find prognostic factors for dis-
ease response. CD remission rates with CS therapy are reported 
to be 70% to 85%, but with maintenance, rates drop down to 
32% to 45% 1 year after CS therapy.11,17 In this study, the short-
term (1 month) response rate was 89.6%, which is similar to the 
results of previous studies. Despite strict definition of remission 
in our study, the short-term CD remission rate after CS therapy 
in our population was relatively higher compared to the rates 
in Western population. The long-term (1 year) response rate 
was also higher in our study group (56.6%) than in previous 
studies.10,17 Better response rates in our study suggest that there 
may be an ethnic difference in CD. Generally, the incidence, 
sex, and clinical phenotypic distribution of Asian CD patients 
are considered somewhat different from those of Westerners.12-16 
Furthermore, recent studies revealed genetic differences between 
Asian and Western CD populations. NOD2 mutations, associated 
with increased susceptibility to CD among Caucasians, do not 
have a significant correlation with CD patients in Asia.27,28 In 
contrast, the TNFSF15 gene has been found to have a stronger 
association with CD in Asians than in Western CD patients.29,30 
Table 2. Comparison of Clinical Factors between Steroid Responders and Nonresponders
Responders
(n=86 [1 mo], 66 [4 mo], 47 [1 yr])
Nonresponders
(n=10 [1 mo], 29 [4 mo], 36 [1 yr])
p-value
Sex, M/F
   1 mo 67/19 8/2 1.000
   4 mo 52/14 22/7 0.791
   1 yr 35/12 27/9 1.000
Age at diagnosis, yr
   1 mo 22.5 (12-64) 23.0 (14-39) 0.957
   4 mo 22.5 (13-64) 23.0 (12-62) 0.677
   1 yr 23.0 (16-64) 22.5 (12-62) 0.923
Disease duration, mo
   1 mo 6.0 (0-156) 1.5 (1-14) 0.115
   4 mo 6.0 (0-156) 2.0 (0-118) 0.181
   1 yr 9.0 (0-156) 3.0 (0-118) 0.338
CDAI
   1 mo 337.0 (161.4-474.2) 386.5 (347.6-559.8) 0.008
   4 mo 311.8 (161.4-451.9) 387.8 (293.7-559.8) <0.001
   1 yr 321.1 (161.4-456.6) 380.6 (208.5-471.9) 0.009
Initial steroid dose, mg/kg
   1 mo 0.58 (0.31-0.95) 0.59 (0.48-0.91) 0.815
   4 mo 0.59 (0.31-0.95) 0.56 (0.35-0.94) 0.580
   1 yr 0.58 (0.31-0.95) 0.62 (0.35-0.94) 0.182
Total steroid dose, mg
   1 mo 1,000.0 (342.5-2,865.0) 1,751.3 (622.5-2,887.5) 0.032
   4 mo 986.3 (342.5-2,065.0) 1,175.0 (342.5-2,887.5) 0.070
   1 yr 972.5 (342.5-2,887.5) 1,227.8 (560.0-2,680.0) 0.078
Location of Crohn’s disease, L1/L2/L3/L4
   1 mo 18/9/54/5 0/1/7/2 0.146
   4 mo 13/7/43/3 5/2/18/4 0.472
   1 yr 9/6/30/2 7/3/23/3 0.828
Behavior of Crohn’s disease, B1/B2/B3
   1 mo 50/12/24 3/1/6 0.109
   4 mo 41/11/14 12/2/15 0.013
   1 yr 28/6/13 17/4/15 0.417
Data are presented as number or median (range).
CADI, Crohn’s disease activity index.
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While the exact etiology of IBD still remains unclear, the disease 
is thought to result from dysregulation of the immune system 
when individuals with susceptible genes are exposed to envi-
ronmental factors.1 Considering such genetic differences, treat-
ment responses can also be expected to differ among races.
One distinctive aspect of our study was that treatment re-
sponse was evaluated after four months of therapy. Because 
three months are generally required for steroid tapering and dis-
continuation, we sought to evaluate the treatment response im-
mediately after the completion of CS therapy by examining the 
Table 3. Comparison of Biochemical Factors between Steroid Responders and Nonresponders
Responders
(n=86 [1 mo], 66 [4 mo], 47 [1 yr])
Nonresponders
(n=10 [1 mo], 29 [4 mo], 36 [1 yr])
p-value
C-reactive protein, mg/dL
   1 mo 2.56 (0.10-14.70) 6.96 (0.13-19.90) 0.015
   4 mo 2.44 (0.10-14.70) 4.25 (0.10-19.90) 0.009
   1 yr 2.55 (0.10-12.40) 3.74 (0.10-19.90) 0.393
ESR, mm/hr
   1 mo 39.5 (2-120) 61.5 (12-120) 0.043
   4 mo 38.0 (2-120) 50.0 (4-120) 0.044
   1 yr 40.0 (2-116) 45.0 (4-120) 0.161
Hemoglobin, mg/dL
   1 mo 12.2 (5.7-16.4) 12.3 (10.6-14.2) 0.986
   4 mo 12.3 (5.7-16.4) 12.1 (7.1-14.2) 0.115
   1 yr 12.2 (5.7-16.4) 12.2 (7.9-15.5) 0.520
Albumin, mg/dL
   1 mo 3.7 (2.1-5.5) 3.6 (2.6-4.1) 0.177
   4 mo 3.7 (2.1-5.5) 3.6 (2.3-5.3) 0.051
   1 yr 3.7 (21-5.5) 3.6 (2.3-5.3) 0.218
Data are presented as median (range).
ESR, erythrocyte sedimentation rate.
Table 4. Multivariate Analysis of Clinical and Biochemical Predictors between Steroid Responders and Nonresponders*
 Variable
1 mo 4 mo 1 yr
p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI)
Age 0.907 1.01 (0.93-1.09) 0.268 1.03 (0.97-1.10) 0.528 1.02 (0.96-1.07)
Location
   L1              - 0.500 0.43 (0.04-5.00) 0.698 0.63 (0.06-6.53)
   L2 0.655 0.45 (0.01-14.64) 0.479 0.36 (0.02-6.06) 0.625 0.53 (0.04-6.75)
   L3 0.530 0.44 (0.04-5.61) 0.149 0.20 (0.02-1.77) 0.358 0.37 (0.04-3.12)
   L4 Reference Reference Reference
Behavior
   B1 0.084 0.23 (0.04-1.22) 0.025 0.25 (0.77-0.84) 0.345 0.59 (0.20-1.76)
   B2 0.688 0.59 (0.04-7.80) 0.150 0.23 (0.03-1.70) 0.730 0.75 (0.14-3.92)
   B3 Reference Reference Reference
Biochemical
   CRP 0.451 1.11 (0.85-1.45) 0.732 0.96 (0.77-1.20) 0.207 0.89 (0.73-1.07)
   ESR 0.652 1.01 (0.98-1.03) 0.071 1.02 (1.00-1.04) 0.056 1.02 (1.00-1.04)
   Albumin 0.483 1.80 (0.35-9.21) 0.635 1.30 (0.44-3.88) 0.931 1.04 (0.41-2.66)
   CDAI 0.140 1.01 (1.00-1.03) 0.002 1.02 (1.00-1.04) 0.029 1.01 (1.00-1.02)
OR, odds ratio; CI, confidence interval; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; CADI, Crohn’s disease activity index.
*The reference is steroid nonresponders.
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response rate after four months. The results of our study showed 
that steroid response rates decrease gradually after inducing re-
mission.
Although CS is an established treatment option for inducing 
remission in active CD, there is no consensus on an optimal 
dose or route of administration. Previous studies have reported 
an appropriate oral prednisolone dose to start at 0.8 to 1.0 mg/
kg when the goal of treatment is remission of the disease.17,22,23,31 
However, in this study, patients showed relatively high remis-
sion rates at a median CS dose of 0.58 mg/kg. Although the 
potential causes of the effects at low doses are difficult to assess 
because of the retrospective design of our study, these findings 
suggest that oral administration of 0.58 mg/kg/day of predniso-
lone may be a sufficient therapeutic dose for Asian CD patients. 
These observations warrant future investigation.
In order to predict the response rate to CS therapy, clinical 
and biochemical factors of the responder and nonresponder 
groups were analyzed. The CDAI of the nonresponder group 
was significantly higher than that of the responder group, and 
this result was repeatedly confirmed at 1 month, 4 months, and 
1 year after treatment. Also, CRP and ESR tended to be higher 
in the nonresponder group. It is well known that CRP is an ef-
fective means of estimating CD activity32 and that ESR can be 
a predictive factor of recurrence in inactive CD patients.33 High 
levels of these parameters and a high CDAI score can represent 
severe inflammation. Therefore, the more severe the inflamma-
tion in CD is, the lower the expected response to CS therapy.
The median serum albumin level was higher in the responder 
group than in the nonresponder group at all times. In IBD, de-
creased serum albumin level is explained by several different 
mechanisms, but its predominant cause is thought to be albu-
min loss through highly permeable mucosal membranes of the 
intestine. Furthermore, lower levels of albumin are associated 
with increased disease severity and degree of inflammation.34 As 
a consequence, lower serum albumin levels in the nonresponder 
group in our study may indicate increased inflammation in 
CD, which is consistent with the results from another Korean 
study.35
 Multivariate analysis showed that CDAI and nonstricturing, 
nonpenetrating type disease behavior (B1) could be predictors of 
treatment outcomes. However, larger scale prospective studies 
are necessary in order for these predictors to be considered for 
clinical application.
This study has several limitations related to the small sample 
size and retrospective study design. For example, smoking 
history, which was known to have adverse effects on disease 
course, was not evaluated. However, the current study also has 
many strong points. In addition to the homogenous sample 
population, patients who received their first CS therapy were 
studied here. Moreover, clinical response in CD patients treated 
with oral CS therapy has not been widely studied before.
In conclusion, our study demonstrated that high rates of 
short-term response to initial oral CS therapy in CD at rela-
tively low doses of CS. Additionally, response rates showed a 
strong tendency to decrease with time. By analyzing different 
responses at various time periods after CS therapy, our study 
determined that CDAI and nonstricturing, nonpenetrating be-
havior as predictive factors that can be used to identify steroid 
responders. Further prospective studies are warranted to confirm 
independent predictive factors.
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